OP Asset Management Ltd Buys Shares of 150,097 Boston Scientific Corporation $BSX

OP Asset Management Ltd purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the first quarter, HoldingsChannel.com reports. The firm purchased 150,097 shares of the medical equipment provider’s stock, valued at approximately $9,419,000.

A number of other institutional investors have also made changes to their positions in the stock. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at about $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Colonial Trust Co SC increased its stake in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank raised its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific’s growth prospects, pointing to upcoming catalysts like pulse field ablation (PFA) and Watchman, and TD Cowen reiterated a Buy rating with a lowered price target that still implies meaningful upside. TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)
• Positive Sentiment: Unusually heavy call option buying suggests traders are positioning for a rebound in BSX, which can reflect bullish near-term sentiment.
• Positive Sentiment: Short interest fell sharply in June, dropping 48.3% to about 29.8 million shares, which may indicate easing bearish conviction and could reduce downside pressure.
• Positive Sentiment: One commentary piece argued that Boston Scientific’s pullback may be creating a value opportunity, reinforcing the view that some investors see the stock as oversold. Boston Scientific’s Fall From Penthouse To Doghouse Creates A Value Opportunity
• Neutral Sentiment: A recent note said BSX has been a laggard this year, and although analysts see upside from current levels, the stock is still working to recover from a sharp decline.
• Negative Sentiment: Boston Scientific recently disclosed a nationwide recall of Orca valves after a device malfunction, adding regulatory and operational concerns that may weigh on sentiment. Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction
• Negative Sentiment: Investors also remain focused on questions around Watchman and the impact of the device recall, which have changed the investment story and may be contributing to recent stock weakness. How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 9,800 shares of company stock worth $554,012. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $44.20 on Friday. The stock has a 50-day moving average price of $53.28 and a two-hundred day moving average price of $71.32. The stock has a market cap of $65.70 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1 year low of $43.89 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BSX. Raymond James Financial restated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Needham & Company LLC reissued a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a report on Monday, May 18th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Finally, UBS Group reduced their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.